RELMADA THERAPEUTICS, INC. (RLMD): auditor change — Relmada Therapeutics dismisses Marcum, appoints CBIZ CPAs as auditor after CBIZ acquisition of Marcum's attest business

RELMADA THERAPEUTICS, INC.

Marcum dismissed as independent auditor on May 8, 2025, following CBIZ CPAs' Nov 1, 2024 acquisition of Marcum's attest business.
CBIZ CPAs engaged as new auditor for fiscal year ending Dec 31, 2025; audit committee approved both actions.
Marcum's reports for 2024 and 2023 contained an explanatory paragraph about substantial doubt as a going concern.
No disagreements or reportable events occurred between Relmada and Marcum during the relevant periods.
Marcum furnished a letter to the SEC agreeing with the disclosures in this filing.

item 4.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

RELMADA THERAPEUTICS, INC. engaged CBIZ CPAs P.C. as its auditor.

Action: engagement
Auditor: CBIZ CPAs P.C.

Exact text from the filing

On May 8, 2025, with the approval of the Company’s audit committee, CBIZ CPAs was engaged as the Company’s new independent registered public accounting firm for the fiscal year ending December 31, 2025.

View on SEC.gov

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

RELMADA THERAPEUTICS, INC. dismissed Marcum LLP as its auditor.

Action: dismissal
Auditor: Marcum LLP
Successor: CBIZ CPAs P.C.

Exact text from the filing

On May 8, 2025, the Company dismissed Marcum as the Company’s independent registered public accounting firm as a result of such acquisition, and the Company’s audit committee approved the dismissal.

View on SEC.gov

8 auditor changes filed in the last 30 days. Browse all auditor changes →

RELMADA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001213900-25-042024

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.